Research Alert

Newswise — Mesenchymal stem cells (MSCs) are a prevalent source for stem cell therapy and play a crucial role in modulating both innate and adaptive immune responses. Non-alcoholic fatty liver disease (NAFLD) is characterized by the accumulation of triglycerides in liver cells and involves immune system activation, leading to histological changes, tissue damage, and clinical symptoms. A recent publication by Jiang et al, highlighted the potential of MSCs to mitigate in NAFLD progression by targeting various molecular pathways, including glycolipid metabolism, inflammation, oxidative stress, endoplasmic reticulum stress, and fibrosis. In this editorial, we comment on their research and discuss the efficacy of MSC therapy in treating NAFLD.

Key Words: Mesenchymal stem cells; Liver regeneration; Non-alcoholic fatty liver disease; Immune cells; Therapeutic strategy

Core Tip: This editorial discusses a recent article published in the World Journal of Stem Cells, which presents mesenchymal stem cells as a promising therapeutic approach for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. The study emphasizes targeting key molecular pathways such as glycolipid metabolism, inflammation, oxidative stress, endoplasmic reticulum stress, and fibrosis. We provide insights into their findings and explore relevant topics in this field.



Journal Link: Publisher Website Journal Link: Download PDF

MEDIA CONTACT
Register for reporter access to contact details
CITATIONS

Publisher Website; Download PDF